Saint John's Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Saint John's Cancer Institute sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Saint John's Cancer Institute: 19 sponsored US clinical trials, 2 recruiting.
Saint John's Cancer Institute sponsors 19 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Carcinoma in Situ, with 1 trials.
Top-decile sponsor footprint
Saint John's Cancer Institute ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (64.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
19 total, page 1 of 1
Pembrolizumab and Pemetrexed for Progressive Chordoma
NCT06794645
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
NCT04603209
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.
NCT05289466
Pemetrexed for the Treatment of Chordoma
NCT03955042
The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition
NCT04082611
CancerLife: Patient-Driven Solution in Cancer Care
NCT03371147
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
NCT03425292
Evaluation of a Mobile Digital Solution for Cancer Care and Research
NCT03094741
An Exploratory Study of Caregiver Burden Among Family Caregivers of Patients With Cancer
NCT03069105
Mitigating Cephalad Fluid Shifts: A NSBRI Study
NCT03097523
Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy
NCT03709888
A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas
NCT02375984
Mindful Movement for Breast Cancer Survivors
NCT02619292
Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain
NCT02548637
Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration
NCT02339987
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
NCT01861717
Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers
NCT01856036
Stage IV Surgery Versus Best Medical Therapy
NCT01013623
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
NCT00297895
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Saint John's Cancer Institute pipeline
2 recruiting of 19 indexed (11% open); 11 completed (58%).
Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Breast Carcinoma in Situ (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Saint John's Cancer Institute: open-pipeline peers nationwide
Peers matched on 19 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Saint John's Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 trials (± recruiting share)
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Corewell Health West · 11% recruiting · 38 trials
- Ethicon · 11% recruiting · 38 trials
- Rowan University · 11% recruiting · 19 trials
- Sun Pharmaceutical Industries Limited · 11% recruiting · 38 trials
Related
What to do with this Saint John's Cancer Institute page
19 registered trials is a research-attention snapshot, not an endorsement of Saint John's Cancer Institute or any single study.
- 2 of Saint John's Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Carcinoma in Situ is the condition Saint John's Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Carcinoma in Situ trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Saint John's Cancer Institute pipeline card: 19 registered trials from official public datasets.Report a data error.